Safety and Efficacy of Aficamten in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A 96-Week Analysis From FOREST-HCM.

IF 8.2 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Cardiac Failure Pub Date : 2025-09-28 DOI:10.1016/j.cardfail.2025.09.016

Ahmad Masri, Mark V Sherrid, Lubna Choudhury, Pablo Garcia-Pavia, Christopher M Kramer, Roberto Barriales-Villa, Robert M Cooper, Perry M Elliott, Sheila M Hegde, Martin S Maron, Michael E Nassif, Artur Oreziak, Anjali T Owens, Scott D Solomon, Albree Tower-Rader, Stephen B Heitner, Daniel L Jacoby, Stuart Kupfer, Fady I Malik, Chiara Melloni, Tyrell Simkins, Jenny Wai, Sara Saberi

引用次数: 0

查看原文本刊更多论文

Aficamten在非阻塞性肥厚性心肌病患者中的安全性和有效性：来自FOREST-HCM的96周分析

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Cardiac Failure 医学-心血管系统

CiteScore

7.80

自引率

8.30%

发文量

653

审稿时长

21 days

期刊介绍： Journal of Cardiac Failure publishes original, peer-reviewed communications of scientific excellence and review articles on clinical research, basic human studies, animal studies, and bench research with potential clinical applications to heart failure - pathogenesis, etiology, epidemiology, pathophysiological mechanisms, assessment, prevention, and treatment.